Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 3/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513455 | 1.00 | LPL (0.46) | LPLLIPGMEN1POLBMAPK1 | |
| SCHEMBL19335428 | 0.87 | LPL (0.37) | LPLLIPGMEN1POLBMAPK1 | |
| SCHEMBL9918 | 0.87 | LPL (0.43) | LPLLIPGAHRCYP2A6 | |
| SCHEMBL30052604 | 0.87 | LPL (0.43) | LPLLIPGAHRCYP2A6 | |
| SCHEMBL19669343 | 0.84 | MEN1 (0.38) | LPLLIPGMEN1POLBMAPK1 | |
| SCHEMBL3195954 | 0.81 | AHR (0.43) | MEN1POLBMAPK1KMT2AAHR | |
| SCHEMBL3792136 | 0.78 | LIPG (0.60) | LPLLIPGBRD4 | |
| SCHEMBL31304657 | 0.78 | LPL (0.42) | LPLLIPGIRAK4 | |
| SCHEMBL2171645 | 0.78 | LPL (0.42) | LPLLIPGIRAK4 | |
| SCHEMBL29644319 | 0.78 | LPL (0.62) | LPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981867-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-20 | — | — | US | claimed |
| US-20200239415-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2020-07-30 | — | — | US | claimed |
| US-7507262-B2 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | claimed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | claimed |
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-11-11 | — | — | US | disclosed |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4155293-B1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4531858-A1 | NOVEL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20250063947-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | HELIATEK GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20090144914-A1 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | LIM MU LLL | 2009-06-11 | — | — | US | disclosed |
| US-7507262-B2 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | disclosed |
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1730116-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092863-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239415-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | LPL 2143/4885LIPG 2380/4885MEN1 30/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | LPL 3658/4885LIPG 3363/4885MEN1 878/4885 |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | LPL 3771/4885LIPG 3523/4885MEN1 1186/4885 |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | LPL 2143/4885LIPG 2380/4885MEN1 30/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | LPL 3010/4885LIPG 3163/4885MEN1 825/4885 |
| US-20090144914-A1 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | KRT18, AKR7A2, AKR1C4 | LPL 3490/4885LIPG 3289/4885MEN1 4624/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | LPL 2910/4885LIPG 2079/4885MEN1 2806/4885 |
| US-20250063947-A1 | COMPOUND AND ITS USE IN ORGANIC ELECTRONIC DEVICES | CYP2C19, CYP2C9, CYP2E1 | LPL 4428/4885LIPG 2506/4885MEN1 799/4885 |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | KRT18, AKR7A2, AKR1C4 | LPL 3490/4885LIPG 3289/4885MEN1 4624/4885 |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | LPL 1506/4885LIPG 1396/4885MEN1 4820/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | LPL 1450/4885LIPG 2704/4885MEN1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.